A New Approach to Conjugate Vaccines

Company Overview

TRIA Bioscience is a privately-held company focusing on the development of a new generation of conjugate vaccines. Scientists at TRIA are using a proprietary synthetic peptide to achieve robust immune responses to traditionally weak antigens. These vaccines are very simple in design, their targets are specific, and their reduced manufacturing costs are unmatched by current technologies.



Conjugate vaccines are among the most successful vaccines developed to date with combined sales of nearly $10B per year. Current conjugate vaccines are very effective in preventing pneumonia and meningitis and induce antibodies to bacterial polysaccharides. This technology requires the chemical conjugation of weak antigens to a protein carrier to improve immunogenicity.

The Problem

Despite their success, conjugate vaccines are expensive to manufacture, and the protein carriers and conjugation reactions create problems that diminish vaccine activity. Unfortunately, new conjugate vaccines for infectious disease have not been approved, nor has this approach succeeded in treating diseases that use other weak antigens including carbohydrates, short peptides, and small molecule drugs.

Our Solution

TRIA Bioscience is pioneering a new approach to conjugate vaccines where traditional protein carriers are replaced with a much smaller synthetic peptide and antigens are attached using new proprietary methods. These vaccines are very simple in design and their manufacturing generates a cost-effective product unmatched by current technologies.

A New Conjugate Vaccine Carrier

  • Synthetic peptide just 65 amino acids in length
  • Two functional domains that activate B- (blue) and T-cells (green)
  • Eliminates the complexities of traditional vaccine carriers
  • Streamlines manufacturing and the regulatory approval process


Addiction Nicotine
Animal Healh Immunocastration
Viral Infection Influenza
Alzheimer's Disease Beta-Amyloid
Brain Injury Tau


TRIA Bioscience has built a vaccine platform for treating drug addiction that includes nicotine. Smoking is the second leading cause of death in the world.  An estimated 1.3 billion people use tobacco products and 50% of these users will die from a smoking related disease.  This project is being funded by a $6.3M grant from the National Institute of Drug Abuse.

Animal Health

The second candidate is an animal health product that provides a safe more humane and economical alternative to surgical castration of food source livestock. Additional uses includes fertility and overpopulation control of domestic animals and wildlife.